author-photo

Ann Janssens

Katholieke Universiteit Leuven
Universitaire Ziekenhuizen Leuven

136

Papers

1960

Citations

Citation Trend

Filter By

Papers (136) Sort By

JournalConferenceOthers

Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
EFFECTIVENESS AND SAFETY OF IBRUTINIB IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MANTLE CELL LYMPHOMA (MCL) IN BELGIAN ROUTINE CLINICAL PRACTICE WITH A 3-YEAR FOLLOW-UP

2021 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Elevate-TN four-year follow up.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Time-Limited Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Who Have Undetectable MRD – Primary Analysis from the Randomized Phase II Vision HO141 Trial

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.

2021 Leukemia
Show All
- Source
- Cite
- Save
Citations (2)
BIRD-2, a BH4-domain-targeting peptide of Bcl-2, provokes Bax/Bak-independent cell death in B-cell cancers through mitochondrial Ca2+-dependent mPTP opening.

2021 Cell Calcium
Show All
- Source
- Cite
- Save
Citations (8)
First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study).

2021 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (1)
Quantitative Whole-Body Diffusion-weighted MRI after One Treatment Cycle for Aggressive Non-Hodgkin Lymphoma Is an Independent Prognostic Factor of Outcome.

2021
Show All
- Source
- Cite
- Save
Citations (0)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号